MT1X and neoplasm: Importantly, tumor cells were highly responsive to copper chelation therapy with a significant decrease in gene expression of the metallothioneins Mt1 and Mt2 as surrogate markers for intracellular copper levels (both p < 0.0001) (Fig. 4c)25.